#Israel #OncoHost #PROphet #Binyamina #BioTech Awards

OncoHost Recognized with 'Proteomics Innovation of the Year'

OncoHost, an innovative technology company revolutionizing precision medicine, recently announced its triumph at the fifth annual BioTech Breakthrough Awards. The company received the prestigious title of 'Proteomics Innovation of the Year,' awarded by BioTech Breakthrough, an esteemed market intelligence organization.

The recognition comes as OncoHost's work in proteomics is increasingly viewed as a game-changer in oncology. Their flagship platform, PROphet®, utilizes advanced proteomic pattern recognition, bioinformatics, and artificial intelligence (AI) to enhance clinical decision-making for oncologists. Its primary offering, PROphetNSCLC®, is a pioneering liquid biopsy test tailored to aid treatment decisions in patients diagnosed with late-stage non-small cell lung cancer (NSCLC).

Currently available across the United States, PROphetNSCLC® provides invaluable insights to healthcare professionals through a single blood sample taken before treatment. This sample captures dynamic biological processes in real time, enabling oncologists to formulate personalized and effective therapy strategies for their patients.

At the heart of OncoHost's proteomics platform lies the ability to identify circulating protein patterns linked to therapy resistance, sensitivity, and potential toxicity. By employing high-throughput assays, a multitude of proteins are analyzed, leading to patient-specific predictive scores for progression-free survival (PFS) and overall survival (OS). The platform's capabilities extend beyond NSCLC, demonstrating predictive value in various cancers, including melanoma, renal cell carcinoma (RCC), HPV-associated cancers, triple-negative breast cancer (TNBC), small cell lung cancer (SCLC), and colorectal cancer.

Furthermore, OncoHost has introduced PROphetirAE™, another innovative proteomics-based model designed to predict immune-related adverse events prior to commencing treatment. This proactive approach allows oncologists to identify patients at risk for significant toxicities, ensuring safer and more effective therapeutic decisions.

Dr. Ofer Sharon, CEO of OncoHost, expressed gratitude for the recognition, stating, "We are deeply honored to receive the BioTech Breakthrough Award for 'Proteomics Innovation of the Year.' This recognition is a testament to our unwavering dedication to improving patient outcomes through rigorous scientific validation across multinational, multicenter clinical programs. With the support of a world-class team of experts in physics, biology, and clinical practice, we are committed to advancing PROphet® as a transformative platform that will redefine precision oncology."

The BioTech Breakthrough Awards aim to acknowledge outstanding achievements in life sciences and biotechnology, featuring thousands of nominations from over 15 countries. Dr. Bryan Vaughn, Managing Director at BioTech Breakthrough, highlighted the significance of OncoHost's innovative approach, stating, "OncoHost represents a paradigm shift toward a host-response proteomics approach that is crucial for enhancing the quality of outcomes in oncology. The initiative to provide reliable, clinically validated biomarkers addresses the current gaps in actionable insights for oncologists, thereby transforming precision medicine practices."

OncoHost's journey is characterized by an experienced leadership team with expertise in entrepreneurship and industry insights, bolstered by an extensive clinical trial involving over 1,700 recruited patients from more than 40 clinical sites globally. The company is well-positioned to spearhead advancements in precision diagnostics and biomarker development.

For more details, visit their official website or engage with OncoHost through social media platforms including LinkedIn, Twitter, Facebook, and YouTube.

In summary, OncoHost's award-winning contributions not only highlight technological advancements in proteomics but also underscore their commitment to enhancing treatment outcomes for patients battling cancer. The optimism surrounding these technologies is justified, as they hold promise for a future where personalized medicine is the norm rather than the exception.